Vertically integrated, medical device contract manufacturing organization serving the medical device, diagnostics and drug delivery markets Cadence, Inc. announced on Thursday that it has named Bob White as a new director.
White brings more than 25 years of leadership experience in operational excellence, innovation, and strategic growth. White previously held senior roles at Medtronic, GE Healthcare and IBM, demonstrating expertise in managing global operations. As executive vice president and group president at Medtronic, he led 25,000 employees across 70 countries, overseeing five global businesses and driving above-market growth. White also executed seven acquisitions, a joint venture and a multi-billion-dollar divestiture. Currently, he serves as an Independent Director for Smith & Nephew and formerly held board positions at Mozarc Medical and CARE Hospitals. His background in medical device manufacturing and strategic insight will enhance Cadence's leadership team.
Matt Jennings, Cadence's chairman of the board, said, 'Bob will be an excellent addition to our board. His impressive track record in global business leadership and his commitment to innovation and growth will be instrumental as Cadence continues to advance its strategic goals and drive success, and he will be valuable to both the Board and Cadence's leadership team with their go-to market approach.'
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Clario acquires imaging provider NeuroRx
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval